
*At this time, there are no current CDC guideline or local rules and regulations in place for COVID-19. As such, this meeting will not require proof of vaccination or testing, and while masking is encouraged, it will be optional. As the course of the pandemic shifts or local, state or federal regulations change, we will follow science and update all attendees. For international attendees, please make sure to check the rules on arrival and departure with your country and the United States. The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 15th Annual PD Therapeutics Conference is scheduled to be held on October 19, 2023, in New York.
Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
Thank you for your tremendous enthusiasm for this year's event. Registration has reached its maximum capacity. We will shortly inform those who had joined the waitlist about their potential to attend.
For any questions, please contact researchmeetings@michaeljfox.org.
Jamie Adams, MD | University of Rochester
Tien Dam, MD | Biogen
Vicky DiBiaso, PhD | Sanofi
Jamie Eberling, PhD | The Michael J. Fox Foundation
Tanya Fischer, MD, PhD | Biohaven
Alison Handler, PharmD, RPh | Novartis
Karl Kieburtz, MD, MPH | University of Rochester
Catherine Kopil, PhD | The Michael J. Fox Foundation
Ken Marek, MD | Institute for Neurodegenerative Disorders
Soania Mathur, MD | MJFF Patient Council Member
Kalpana Merchant, PhD | TransThera Consulting
Tom Montine, MD, PhD | Stanford University
Karoly Nikolich, PhD | Alkahest Inc.
Gennaro Pagano, MD, PhD | Roche
Niels Plath, PhD | Muna Therapeutics
Kathleen Poston, MD, MS | Stanford University
Gary Rafaloff | MJFF Patient Council Member
Andrew Singleton, PhD | National Institutes of Health
David Stone, PhD | Cerevel Therapeutics
Bill Shrader, PhD | AcureX
Paul Thompson, PhD | Mission Therapeutics
Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute
-
Poster Presentations
Path to Prevention (P2P) Trial: Study Design and Status Update
Tanya Simuni, MD | Northwestern University
A Machine Learning Contest to Automatically Detect Freezing of Gait: Results and Insights
Jeff Hausdorff, PhD | Tel Aviv Medical Center
Aligning with Regulators to Advance Patient-Reported Outcome Assessments that are Fit-for-Purpose in Early-Stage Parkinson’s Disease Clinical Trials
Diane Stephenson, PhD | Critical Path Institute
The London-Dhaka Project – the Prevalence and Assessment of Cognitive Impairment in Parkinson’s Disease
Alastair Noyce, MSc, MRCP, PhD, FHEA | Queen Mary University of London
Hit-to-Lead STING Inhibitor Small Molecule Development for Parkinson’s Disease
,John Streiff, PhD | AeroNeph Therapeutics
The Lysosomal Polyamine Transporter ATP13A2, an Emerging Drug Target for Parkinson’s Disease
Peter Vangheluwe, PhD | KU Leuven
MJFF Tools Overview
Nicole Polinski, PhD | MJFF
The National Plan to End Parkinson’s Act
Dustin Watson | MJFF
The 15th annual Parkinson's Disease Therapeutics Conference is made possible by the support of our generous sponsors:

Interested in Sponsorship Opportunities?
View our sponsorship opportunities menu to support this year's conference.
Contact our Research Alliances team at researchpartnerships@michaeljfox.org with questions.
-
2022 Conference
-
2020-2021 Webinars
-
2019 Conference
-
2018 Conference
-
2017 Conference
-
2016 Conference
-
2015 Conference
-
2014 Conference
-
2013 Conference
-
2012 Conference
-
2011 Conference
-
2010 Conference
-
2009 Conference